... combined in a model, coulddiscriminate the treating rheumatologist's decision to give adose increase of infliximab to RA patients not optimallyresponding to an indicated dose of 3 mg infliximab ... systemic inflammation.Infliximab, in combination with methotrexate (MTX), is a highlyeffective therapy for a majority of RA patients. After an induc-tion scheme at weeks 0, 2 and 6, the indicated ... 511 patients, suffering from active refractory RA [5],were treated with intravenous infusions of infliximab (3 mg/kg)at weeks 0, 2, 6 and every 8 weeks thereafter in combinationwith MTX (a minimal...